|Videos|February 4, 2021
Tarsus execs discuss origins, treating Demodex blepharitis
Author(s)OT Staff Reports
Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Treating myopia today: US-focused treatments, challenges, and global insights
2
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
3
FDA clears BVI’s FineVision HP trifocal IOL for the US market
4
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
5